Generic Name: brexucabtagene autoleucel
Brand Name: TBC
Manufacturer: Gilead Sciences Canada Inc.
Therapeutic Area: Mantle cell lymphoma
Indications: For the treatment of adult patients with relapsed or refractory (r/r) mantle cell lymphoma (MCL) who have received treatment with a Bruton’s tyrosine kinase inhibitor (BTKi).
Manufacturer Requested Reimbursement Criteria1: For the treatment of adult patients with relapsed or refractory (r/r) mantle cell lymphoma (MCL) who have received treatment with a Bruton’s tyrosine kinase inhibitor (BTKi).
Submission Type: Initial
Tumour Type: Lymphoma
Project Status: Pending
Call for patient/clinician input open: November 20, 2020
Call for patient/clinician input closed: January 22, 2021
Anticipated Date: December 18, 2020
Fee Schedule1: Pending
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.